WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Credit Rating
This is to inform you that India Ratings and Research Private Limited has revised the credit ratings of certain banking instruments of the Company as detailed in the attachment. WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') WOCKHARDT LTD. - 532300 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Humuza Consultants & Others WOCKHARDT LTD. - 532300 - Related Party Transactions For Half Year Ended September 30, 2022 Under Reg 23(9) Of SEBI (LODR) Regulations, 2015.
Related Party Transactions for Half year ended September 30, 2022 under Reg 23(9) of SEBI (LODR) Regulations, 2015. WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Wockhardt posts 207 crore loss in Q2FY23
The drugmaker recorded a revenue of 679 crore in the quarter under review, compared to 862 crore in the same period, last year Q2FY23 Quarterly Result Announced for Wockhardt Ltd.
Pharmaceutical company Wockhardt announced Q2FY23 results: The Company recorded a Revenue of Rs.679 crore in Q2FY23 compared to Rs.595 crore in the previous quarter registering a growth of 14%. EBITDA for the quarter is Rs.43 crore as compared to Rs. (16) crore in Q1FY23 registering a substantial growth of 369%. Q2FY23 Global revenue: UK Business stood at Rs.226 crore in Q2FY23 (PY Rs.387 Cr). UK Business contributed about 33% of Global Revenue. India Business: India Business stood at Rs.150 crore (PY Rs.187 crore). India's Business contributed 22% of the Global Revenue. EMROK, the NCE launched during FY21 continues to provide unmatched benefits to patients. The emerging Markets Business of the Company stood at Rs.117 crore in Q2FY23 (PY Rs.165 Cr). Emerging Markets Business contributed about 17% of the Global Revenue. Irish Business stood flat at Rs.38 crore in Q2FY23 compared to the previous year. US Business stood at Rs.89 crore in Q2FY23 compared to Rs.61 crore in the previous year registering a growth of 45%. US Business contributed 13% of the Global Revenue. US business was impacted by price erosion and supply disruptions. Research and Development expenditure during the quarter was at Rs.39 crore (6% to sales) and including capital expenditure was at 11.8% to sales. Result PDF WOCKHARDT LTD. - 532300 - Board Meeting Outcome for Outcome Of The Board Meeting
Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'); and in continuation to our letter no. Ref. No.: WOCK/SEC/SE/2022-23/044 dated 28th October, 2022, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 4th November, 2022, inter-alia, have approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September, 2022; and Limited Review Report issued by B S R & Co. LLP., Statutory Auditors of the Company;